Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for cancer. Its lead product, aglatimagene besadenovec (CAN-2409), is an adenovirus-based immunotherapy administered with prodrug valacyclovir, studied in prostate cancer, non-small cell lung cancer, and pancreatic cancer. The company also has an HSV-based platform. Aglatimagene met its primary endpoint in a phase 3 prostate cancer trial and received FDA RMAT Designation in 2025.
expected 2026-12-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-103134 | EDGAR | 125K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038803 | EDGAR | 116K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037637 | EDGAR | 112K words |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010760 | EDGAR | 111K words |
| 2022-03-29 | 2021-12-31 | 0000950170-22-004857 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001193125-26-347980 | EDGAR | 83K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-279086 | EDGAR | 81K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108450 | EDGAR | 78K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069833 | EDGAR | 74K words |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126767 | EDGAR | 75K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-095784 | EDGAR | 74K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059118 | EDGAR | 72K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061566 | EDGAR | 78K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040984 | EDGAR | 77K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020873 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024197 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0000950170-22-014970 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-10 | 0001193125-26-387310 | EDGAR | 1K words |
| 2026-09-09 | 0001193125-26-386561 | EDGAR | 9K words |
| 2026-08-13 | 0001193125-26-347957 | EDGAR | 3K words |
| 2026-03-12 | 0001193125-26-103126 | EDGAR | 3K words |
| 2026-02-23 | 0001193125-26-062490 | EDGAR | 1K words |
| 2026-02-19 | 0001193125-26-059334 | EDGAR | 1K words |
| 2025-12-05 | 0001193125-25-308719 | EDGAR | 9K words |
| 2025-11-13 | 0001193125-25-279072 | EDGAR | 4K words |
| 2025-10-14 | 0001193125-25-238254 | EDGAR | 2K words |
| 2025-08-21 | 0000950170-25-110682 | EDGAR | 1K words |
120 total filings indexed. 93 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001841387 |
| Ticker | CADL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.candeltx.com |
| Listed | 2021-07-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CADL (~200 tokens, structured JSON with cryptographic provenance)